This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| BAX | |
|---|---|
| Name | BAX |
| Uniprot | P01109 |
| Organism | Homo sapiens |
| Length | 192 aa |
| Location | Mitochondrion |
BAX BAX is a pro-apoptotic member of the BCL-2 protein family that promotes programmed cell death by permeabilizing the outer mitochondrial membrane. It plays central roles in intrinsic apoptosis signaling downstream of stressors such as DNA damage, developmental cues, and immune signaling, integrating inputs from tumor suppressors, oncogenes, and stress-activated kinases. Studies of BAX have connected it to pathways investigated by researchers at institutions such as Harvard University, Massachusetts Institute of Technology, Cold Spring Harbor Laboratory, and Max Planck Society.
BAX was identified in genetic and biochemical screens alongside proteins such as BCL-2, BCL-XL, BAK, BAD, and BID in research labs including those at University of California, San Francisco and Stanford University. Early functional characterization involved groups working with models like Saccharomyces cerevisiae and Mus musculus and leveraged techniques developed at National Institutes of Health and European Molecular Biology Laboratory. The protein has been the subject of landmark publications appearing in journals such as Nature, Science, and Cell and has been discussed in conferences organized by American Association for Cancer Research and Society for Neuroscience.
The human gene mapping to chromosome regions studied by consortia such as the Human Genome Project encodes a 192–amino-acid protein. Structural insights derive from efforts at facilities like Argonne National Laboratory and Brookhaven National Laboratory using methods applied by teams from University of Oxford and University of Cambridge. BAX contains BH (BCL-2 homology) domains analogous to BH1, BH2, and BH3 found in BCL-2 family proteins, and exhibits an alpha-helical fold characterized by data generated at European Synchrotron Radiation Facility and analyzed by groups at Massachusetts General Hospital. High-resolution structures from laboratories including The Scripps Research Institute and Roche revealed conformational changes that expose the BH3 region, comparable to models proposed by scientists at Yale University and University of Chicago.
BAX functions as an executioner in mitochondrial outer membrane permeabilization (MOMP), a process elucidated in studies involving p53, ATM, ATR, CHK1, and CHK2 signaling cascades. Activation involves translocation from cytosol to mitochondria, oligomerization, and pore formation—mechanisms examined using approaches from European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, and Johns Hopkins University. BAX activity is modulated by interactions with BH3-only proteins such as BID, BAD, PUMA, NOXA, and BIM described in research at Dana-Farber Cancer Institute and Fred Hutchinson Cancer Center. Functional assays performed in model systems like Drosophila melanogaster and Caenorhabditis elegans helped link BAX to developmental apoptosis paradigms explored by teams at Columbia University and Rockefeller University.
Regulatory control of BAX involves transcriptional regulation by TP53, post-translational modifications from kinases such as JNK, AKT1, and phosphatases studied at Institute Pasteur, and direct binding by anti-apoptotic proteins including BCL-2, BCL-XL, and MCL1. Interactome mapping using proteomics platforms from European Bioinformatics Institute and ProteomeXchange cited interactions with chaperones studied at Max Planck Institute for Biochemistry and ubiquitin ligases researched at Cold Spring Harbor Laboratory. Cellular localization dynamics were visualized using microscopy methods refined at Max Planck Institute for Cell Biology and imaging centers at University College London.
Aberrant BAX function has been implicated in oncogenesis investigated by researchers at Memorial Sloan Kettering Cancer Center, chemoresistance studies at MD Anderson Cancer Center, and neurodegeneration research in laboratories affiliated with University of California, San Diego and UCL Great Ormond Street Institute of Child Health. Loss-of-function or expression downregulation is observed in malignancies cataloged by The Cancer Genome Atlas and correlates with outcomes reported by groups at Mayo Clinic and Cleveland Clinic. Conversely, hyperactivation contributes to ischemia-reperfusion injury characterized in studies at Karolinska Institutet and Imperial College London, and to degenerative conditions explored by teams at University of Pennsylvania and Johns Hopkins University Hospital.
Genetic knockout and transgenic mouse models developed at The Jackson Laboratory and studied at Salk Institute have been instrumental in defining BAX roles in lymphopoiesis, spermatogenesis, and neuronal apoptosis. Cell-based assays using lines from repositories such as American Type Culture Collection and CRISPR screens performed at Broad Institute revealed synthetic lethal interactions with genes investigated by researchers at Wellcome Trust Sanger Institute and European Molecular Biology Laboratory. Structural and biophysical studies employed NMR and cryo-EM facilities at Max Planck Institute for Biophysical Chemistry and National Center for CryoEM to probe oligomerization and pore architecture.
Strategies to modulate BAX include BH3-mimetic drugs developed by pharmaceutical companies such as AbbVie, Roche, AstraZeneca, and startups originating from Cambridge Biomedical Campus; clinical trials have been coordinated with centers like Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Approaches include sensitizing tumors to chemotherapy through modulation of BAX-BCL-2 family interactions, neuroprotective interventions to limit BAX-mediated apoptosis in stroke trials at Massachusetts General Hospital, and gene therapy concepts explored at National Cancer Institute. Biomarker studies leveraging datasets from European Genome-phenome Archive and The Cancer Genome Atlas aim to stratify patients for therapies targeting apoptotic priming.
Category:Proteins Category:Apoptosis Category:Human proteins